Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma

201981 citationsJournal Articlegreen Open Access

Authors

Robert Chen · City of Hope

Alex F. Herrera · City of Hope

Jessie Hou · City Of Hope National Medical Center

Lu Chen · City of Hope

Jun Wu · City Of Hope National Medical Center

Yuming Guo · City Of Hope National Medical Center

Timothy W. Synold ·

Abstract

This study may provide a new therapeutic strategy to combat brentuximab vedotin resistance in Hodgkin lymphoma. This is the first study reporting an effect of multidrug resistance modulation on the therapeutic activity of an ADC in humans. The expansion phase of the trial is ongoing and enrolling patients who are refractory to brentuximab vedotin to confirm clinical activity in this population with unmet need.

Topics & Keywords

Lymphoma Diagnosis and Treatment Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 26, Issue 5, pp. 1034-1044

DOI: 10.1158/1078-0432.ccr-19-1768

Field-Weighted Citation Impact: 5.53